TIGIT-hemmere begynner å vise effekt.
1 Like
Rett etter LAG3-hemming viste litt effekt med Opdivo får TIGIT-hemmeren til Genentech seg et slag over nesen.
Tiragolumab is a novel immune checkpoint inhibitor with an intact Fc region. Tiragolumab selectively binds to TIGIT, a novel inhibitory immune checkpoint, which suppresses the immune response to cancer. Based on preclinical research, tiragolumab is thought to work as an immune amplifier with other cancer immunotherapies such as Tecentriq® (atezolizumab). The TIGIT pathway is distinct but complementary to the PD-L1/PD-1 pathway. Dual blockade with tiragolumab and Tecentriq may help overcome immune suppression and restore the immune response.
2 Likes
https://www.nature.com/articles/s43018-022-00362-5
Further analysis revealed that intratumoral neoantigen-specific CD8+ T cells expressed negative regulators of T cell function, including PD-1 as well as the transcription factor TOX. These features are associated with CD8+ T cells that lack effector function and are designated as dysfunctional or exhausted T cells (Td/ex)13. At the same time, other immune cells within the tumor microenvironment (TME) expressed high levels of PD-L1. Therefore, Liu et al.14 assessed whether ICT antibody blockade of PD-1–PD-L1 interaction in the TME could enhance the efficacy of the neoantigen vaccine. Whereas monotherapy via either neoantigen vaccination or anti-PD-L1 treatment slowed tumor outgrowth, combining neoantigen vaccination and anti-PD-L1 provided superior efficacy and led to complete tumor rejection (Fig. 1a).
1 Like
1 Like